Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Ferring B.V. currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units. SIFFORD, JEFFREY MARK is the busiest examiner, with 1 pending action. This 1:1:1 ratio between actions, examiners, and art units indicates a highly decentralized prosecution profile.
Each pending matter is being evaluated by a unique examiner within a unique art unit, requiring the company to manage three separate sets of examination standards and timelines. The involvement of 3 distinct art units suggests that the technical subject matter of the three applications is sufficiently different to require different specialized groups within the Biotechnology & Pharmaceuticals sector.
The prosecution of these 3 pending actions will likely follow different paths due to the lack of overlap in personnel. This diversity in the examination process means that the company must be prepared for different sets of prior art and different interpretations of patentability. Practitioners should monitor the 3 distinct examiners closely, as no single individual holds a majority of the pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
| BRADLEY, CHRISTINA | 1 | 62.6% | +33.3% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | BRADLEY, CHRISTINA | 22d |
| 18556625 | BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | BRADLEY, CHRISTINA | 22d |
| 18556625 | BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI | SIFFORD, JEFFREY MARK | — |
| 18009469 | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1654 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556625 | BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18266159 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | BRADLEY, CHRISTINA | 1654 | §101§102§103 | Final Rejection | 22d | Pending | Jun 08, 2023 |
| 18009469 | PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | HOWARD, ZACHARY C | 1674 | §103Other | Non-Final OA | — | Pending | Dec 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFerring B.V. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Jeffrey Mark Sifford has the most, with 1 of Ferring B.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
